Concepedia

Hongnan Mo

HM

Statistics

Publications

29

Citations

2.2K

H-Index

20

Active since

2010

Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College(Current)

National Cancer Center

Peking University

Cancer Hospital of Huanxing Chaoyang District Beijing

Peking University Cancer Hospital

Hongnan Mo is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in oncology, medicine, and cancer immunotherapy.

ORCID

Publications per year

2010–2025

29

Publications

29

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

Yuanyuan Zhang, Hongyan Chen, Hongnan Mo et al. · Cancer Cell · 2021 · 786 citations · Full text

, , +17

Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma

Jing Huang, Binghe Xu, Hongnan Mo et al. · Clinical Cancer Research · 2018 · 217 citations

, , +17

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

Hongnan Mo, Jing Huang, Jiachen Xu et al. · British Journal of Cancer · 2018 · 156 citations · Full text

, , +17

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China

Yiqun Li, Nilupai Abudureheiyimu, Hongnan Mo et al. · Frontiers in Oncology · 2022 · 119 citations · Full text

, , +17

Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer

Yuanyuan Zhang, Hongyan Chen, Hongnan Mo et al. · Cancer Cell · 2025 · 115 citations · Full text

, , +17

1–5 of 29